Xellia Pharmaceuticals
Denmark-based Xellia Pharmaceuticals is a specialty pharmaceutical company focusing on providing important anti-infective treatments against serious and often life-threatening infections.
Its anti-infective treatments are generics that combat serious bacterial and antibiotic resistant infections as well as certain fungal diseases.
Since 2013, the company has been wholly-owned by Novo Holdings A/S, which is also a major shareholder in Danish diabetes care giant Novo Nordisk.
Latest Xellia Pharmaceuticals News & Features
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze